In this interview we discuss preliminary results of the COMPASS trial, which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.
Kyaw L. Aung, MBBS, PhD
Advertisement
Articles by Kyaw L. Aung, MBBS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Oral Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
2
FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
3
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?
4
Novel Adenoid Cystic Carcinoma Drug Earns FDA Breakthrough Therapy Status
5